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Linda Rhodes2, Lindsey M Vansandt7, George Robert Weedon2,8, 
Julie Wolf9 and Julie K Levy2,10
Abstract
Objectives Non-surgical contraceptive management of free-roaming cat populations is a global goal for public 
health and humane reasons. The objectives of this study were to measure the duration of contraception following 
a single intramuscular injection of a gonadotropin-releasing hormone-based vaccine (GonaCon) and to confirm its 
safe use in female cats living in colony conditions.
Methods GonaCon (0.5 ml/cat) was administered intramuscularly to 20 intact female cats (queens), and saline was 
administered to 10 queens serving as sham-treated controls. Beginning in late February, 4 months after injection, 
all cats were housed with fertile male cats in a simulated colony environment. Time to pregnancy, fetal counts and 
vaccine-elicited injection-site reactions were evaluated.
Results All control cats (n = 10/10) and 60% (n = 12/20) of vaccinated cats became pregnant within 4 months of 
the introduction of males. Two additional vaccinates became pregnant (70%; n = 14/20) within 1 year of treatment. 
Average fetal counts were significantly lower in vaccinated cats than in control cats. Vaccinates had a significantly 
longer (P = 0.0120) median time to conception (212 days) compared with controls (127.5 days). Injection-site 
reactions ranging from swelling to transient granulomatous masses were observed in 45% (n = 9/20) of vaccinated 
cats.
Conclusions and relevance A single dose of GonaCon provided contraception lasting for a minimum of 1 year in 
30% (n = 6/20) of treated cats. The level of contraception induced by this GonaCon dose and vaccine lot was not 
sufficiently effective to be recommended for use in free-roaming cats.
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Introduction
Control of free-roaming cat (FRC) populations is desired 
by multiple stakeholders to improve the welfare of cats, 
other species and society. While surgical sterilization 
serves as the cornerstone of humane FRC management, 
long-acting non-surgical contraceptive methods are 
being explored as potential cost-effective adjuncts to 
 surgery. GonaCon, a gonadotropin-releasing hormone 
(GnRH) vaccine developed by the US Department of 
Agriculture, Animal and Plant Health Inspection Service 
(USDA APHIS), Wildlife Services’ National Wildlife 
Research Center (NWRC), is one such approach. 
GonaCon Immunocontraceptive Vaccine and GonaCon-
Equine are registered by the US Environmental 
Protection Agency (EPA) for contraception of adult 
female white-tailed deer, and wild horses and burros, 
respectively. GonaCon has undergone several formula-
tion changes since its initial development by the NWRC, 
and the name has been loosely applied in the literature 
to different formulations. All GonaCon formulations 
have included a carrier protein presenting multiple cop-
ies of a GnRH peptide, emulsified in a mineral oil-based 
mycobacterium-containing adjuvant.
Levy et al were the first to demonstrate safety and 
efficacy of a previous formulation of the GnRH vaccine 
in the laboratory using commercial, vendor-acquired, 
specific-pathogen-free female cats.1 Fifteen adult queens 
were injected intramuscularly with 0.5 ml of this GnRH 
vaccine, and five control cats were injected with a sham 
vaccine. In a 5 year breeding trial starting 120 days post-
vaccination, vaccinated cats had a significantly longer 
median time to conception (39.7 months) compared with 
sham-treated cats (4.4 months). Granulomatous injection- 
site masses appeared 2 years after vaccination in 33% 
(n = 5/15) of treated cats. Stochastic modeling suggested 
that this median duration of infertility could position an 
injectable contraceptive to rival permanent sterilization 
of cats for short-term population reduction in the first 5 
years of use, though it would be less effective over the 
longer term of 10 years.2
Owing to changes in vaccine formulation following 
the Levy et al study,1 plus consideration of the potential 
for injection-site reactions, a short-term safety study 
using the current formulation of GonaCon was con-
ducted in six adult spayed female purpose-bred cats at 
the Cincinnati Zoo’s Center for Conservation and 
Research of Endangered Wildlife.3 GnRH antibodies 
developed within 30 days in all vaccinates and persisted 
throughout the 4 month study. Although transient injec-
tion-site reactions were observed in 66% (n = 4/6) of 
cats, the levels of safety and immunogenicity demon-
strated were deemed adequate for further evaluation.
The purpose of the current study was to determine 
the duration of immunocontraception induced by vacci-
nation with 0.5 ml GonaCon in a diverse group of queens 
living under conditions that closely resembled a FRC 
population. It was hypothesized that GonaCon adminis-
tration would result in prolonged and safe contraception 
of female cats under simulated FRC colony conditions. 
The design of the current study, when compared with 
the Levy et al study in female laboratory cats,1 modified 
both the source of animals and their housing conditions. 
Specific study objectives were to measure duration of 
contraception following a single intramuscular injection 
of GonaCon and to confirm the clinical safety of a single 
injection of GonaCon.
Materials and methods
Animals and environment
Forty-five cats (38 females, seven males) were screened 
for potential participation in the study. All were domestic 
short- or medium-hair cats, with estimated ages ranging 
from 4 months to 3 years (females) and 1–3 years (males) 
at the time of screening. Forty cats (33 females, seven 
males) were acquired from four animal control agencies 
in four non-adjacent Illinois counties; efforts were made 
to select cats at high risk of euthanasia. Four cats were 
acquired from private individuals who posted cats for 
rehoming on a classified advertisement website, and one 
from a feline rescue. Six sister pairs were enrolled; beyond 
those sibling relationships, it is expected that the study 
population was genetically diverse owing to geographic 
distribution of cat sources. Cats that were screened but 
not enrolled in the study were surgically sterilized and 
adopted into private homes.
The study was performed at Clowder Concepts, a 
USDA-registered Class R research facility, and all proce-
dures were approved by the facility’s Institutional 
Animal Care and Use Committee. The facility was 
located in a rural community outside of Urbana-
Champaign, IL, USA, and was licensed and inspected by 
the Illinois Department of Agriculture as an animal shel-
ter. Cats were group housed in a 1400-square-foot room 
with a loft and ample opportunities to perch, climb and 
hide. The room was maintained at ambient temperatures 
between 20ºC and 27°C. Cats had access during daylight 
hours to an outdoor fenced enclosure (one-third of an 
acre) with grasses, shrubs and trees. Light provided 
inside the facility was adjusted to reflect the natural 
 photoperiod. Cats were fed a commercial dry cat food 
with access to fresh water ad libitum; canned food and 
treats were provided for enrichment.
Intake and screening procedures
Female cats Prior to entering the facility, each female cat 
underwent a physical examination to rule out pregnancy, 
clinical signs of illness and behaviors incompatible with 
group housing or low-stress handling. Preventive health-
care was provided as described in Table 1. Cats were 
visually assessed twice daily for general wellbeing and 
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received monthly physical examinations and monthly 
treatment with imidacloprid plus moxidectin (Advan-
tage Multi; Bayer) for the duration of the study.
Male cats Male cats were transferred to the facility a 
minimum of 4 months after the females and underwent 
the procedures described in Table 1, except for ultra-
sound examinations. Additionally, all males were 
assessed for fertility. Semen was collected under seda-
tion via urethral catheterization or electroejaculation.4,5 
Immediately after collection, semen was subjected to a 
standardized semen analysis.6
Study design
Thirty female cats were selected based on health and 
behavior. To randomly assign treatment groups, cats 
were listed from youngest to oldest based on estimated 
age. A randomization table was generated assigning 
each female cat to receive either GonaCon or sterile 
saline (control group), starting with cat 1, in groups of 
three (with two GonaCon and one control in each group). 
This randomization resulted in 20 GonaCon-treated cats 
and 10 control cats. With the exception of the veterinar-
ian who administered the injections, the study statisti-
cian and the study monitor, all other study personnel 
were blinded to each cat’s treatment assignment until 
the cat was diagnosed as pregnant. Five male cats were 
selected for use in the study based on health, behavior 
and fertility.
Design and funding allowed for up to a 5 year study 
duration, based on cat safety and vaccine effectiveness. 
Lack of demonstration of vaccine effectiveness in the 
first year led to the decision to terminate the study 1 year 
post-vaccination. All cats were surgically sterilized and 
adopted to private homes at the end of the study.
Vaccination
‘GonaCon’ refers to a formulation identical to the 
GonaCon Immunocontraceptive Vaccine (EPA registra-
tion 56228-40) and GonaCon-Equine (EPA registration 
56228-41) products but applied in a smaller dose for this 
unregistered, experimental use in domestic cats. 
GonaCon was provided by the USDA/NWRC, Fort 
Collins, CO, USA. Pre-filled syringe doses were shipped 
in a cooler with ice packs to the test facility and kept 
under refrigerated conditions until administration. The 
vaccine was kept at a refrigerated temperature from 
manufacture until use, as documented by chain of cus-
tody forms. In order to mimic field conditions, cats were 
not sedated and the injection site was not prepared prior 
to injection of 0.5 ml GonaCon or sterile saline into the 
right quadriceps muscle group using an 18 G needle. 
The day of vaccination was designated study day 0.
Safety observations
Injection sites were palpated daily for 1 week following 
treatment, then weekly for 1 month and then at least 
monthly. Cats were observed daily, and any adverse 
events were recorded on adverse event forms. Baseline 
serum chemistry and hematology analysis was per-
formed prior to vaccination on each cat, and repeated on 
day 34.
Breeding trial
The breeding trial began with the first male cat intro-
duced 115 days after treatment. This date corresponded 
with a period of increasing day length (late February) 
and the time of year typically associated with the begin-
ning of increased feline estrous activity. A rotation of five 
breeding males mitigated effects of inter-cat behavioral 
incompatibility on breeding success. All estrous behav-
iors and breeding attempts that occurred in the presence 
of project personnel were recorded. Cats were not under 
24 h observation, so it is likely that some estrous and 
breeding behaviors went unobserved and unrecorded.
Pregnancy diagnosis and ovariohysterectomy
A veterinarian performed monthly ultrasonographic 
examinations of each queen, beginning 1 month after ini-
tiation of the breeding trial. Cats identified as pregnant 
Table 1 Cat intake and conditioning procedures
Complete physical examination (repeated within 3–4 weeks)
Scanned for presence of microchip
Wood’s lamp examination for ringworm
Vaccination against feline viral rhinotracheitis, calicivirus, panleukopenia/feline leukemia virus (FeLV) (repeated within 3–4 
weeks)
Treatment with imidacloprid/moxidectin and praziquantel
Complete blood count and serum chemistry panel
FeLV antigen and feline immunodeficiency virus antibody test*
Abdominal ultrasonographic examination for general health and pregnancy detection (repeated within 3–4 weeks)
Implantation of RFID microchip
Rabies vaccination
*Cats were individually housed until this test was performed and yielded a negative result. All females were retested on study day 0, which was 
at least 30 days after the initial test
RFID = radio-frequency identification
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were ovariohysterectomized between 0 and 8 days after 
pregnancy was confirmed, and always prior to an esti-
mated day 45 of gestation.
Time to conception was defined as the interval between 
day 0 and conception, which was estimated by measuring 
fetal crown–rump length. The length of each fetus was 
measured with calipers, and the median litter fetal crown–
rump length value was calculated for each litter. Fetal age 
was estimated as per published guidelines.7 If the median 
crown–rump length was <58 mm, the date of conception 
was arbitrarily designated as 30 days prior to the spay 
surgery. Fetuses were visually evaluated for normal 
development, but necropsies were not performed.
Statistical analyses
Differences in the median time to conception between 
the vaccinated and control groups were determined by 
the Kaplan–Meier survival analysis log rank test. Mean 
± SEM and median were calculated for litter size. Means 
and medians were compared using the Student’s t-test 
and Wilcoxon rank-sum test, respectively.
Results
Breeding trial
Time to pregnancy is shown in Figure 1. Six control cats 
(60%) and eight GonaCon-treated cats (40%) displayed 
behavioral signs of estrus and became pregnant within 
the first month of the breeding trial. By the fourth month 
of the breeding trial all control cats (n = 10) had become 
pregnant, as had 12 (60%) of the GonaCon-treated cats. 
At 1 year post-treatment, two additional queens had 
conceived and therefore 14 GonaCon-treated cats (70%) 
had become pregnant. The GonaCon-vaccinated group 
had a longer median time to conception following treat-
ment (212 days) than controls (127.5 days; P = 0.01; 
Figure 1). Litter size (mean ± SD) was significantly 
smaller in the GonaCon-vaccinated group (3.9 ± 1.7) 
compared with the control group (5.6 ± 1.8; P = 0.04) 
(Table 2). There was one unviable (likely resorbed) fetus 
detected in a vaccinate litter and one in a control litter.
Estrous behaviors
Based on observations during working hours (typically 
72 h per week and excluding overnight periods), estrous 
behaviors were never observed in 4/6 vaccinated cats 
that did not become pregnant. The other two vaccinates 
exhibited estrous behaviors, even before the breeding 
trial began, and then engaged in breeding multiple times 
over the course of the study but did not conceive. The 
last vaccinate that conceived (cat 25 on day 273) dis-
played persistent estrous behaviors and accepted the 
males repeatedly for 5 months prior to conception.
Safety
There were a variety of adverse events that occurred 
during the trial that would be expected in a colony of 30 
co-housed female cats, plus a rotation of male cats. 
However, there was no pattern to indicate that any 
adverse events were related to treatment group, with the 
exception of injection-site reactions.
Three vaccinates (cats 9, 21, 36) were observed limp-
ing on the right hindlimb beginning 3–7 h after treat-
ment, which resolved within 24 h. No other acute 
adverse reactions related to vaccination were observed.
Nearly half of the treated cats (n = 9/20) had a 
delayed (beginning at least 1 month after treatment) 
injection-site reaction in the region in which GonaCon 
was administered. Seven of these cats developed soft 
 tissue masses near the site of injection at variable time 
points, and mass size fluctuated over variable durations. 
The other two cats developed swelling with no palpable 
mass.
Reactions for six cats with delayed reactions resolved 
within 2–3 months post-injection, whereas reactions for 
three cats were detected during or after month 7 and per-
sisted through their adoption and exit from the study. 
Among these nine cats with delayed injection-site reac-
tions, none demonstrated prolonged pain or difficulty 
ambulating, and there was no evidence of ulceration or 
other external irritation. A summary of injection-site 
reactions is presented in Table 3.
Wedge biopsies were performed under general anes-
thesia on two of the later-onset masses (cats 8 and 18). 
Histological evaluation indicated the lesions were gran-
ulomatous to pyogranulomatous panniculitis with 
inter-lesional acid-fast bacteria. Aerobic, anaerobic and 
Figure 1 Fertility control in cats. Vaccinated cats (n = 20) 
received an intramuscular (IM) injection of GonaCon on 
study day 0. Control cats (n = 10) received an IM injection 
of saline. A breeding trial commenced on study day 115 and 
terminated on day 363. Vaccinated cats had longer median 
time to conception (212 days) than control cats (127.5 days; 
P = 0.0120). Six vaccinated cats remained infertile for the 
duration of the breeding trial
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mycobacterial cultures performed on tissue from cat 18 
were negative; tissue from cat 8 was not cultured. 
Mycobacteria PCR was negative for cat 8 (formalin-
fixed tissue) and cat 18 (fresh tissue).
Two of the cats with masses did not become pregnant, 
and five became pregnant between days 123 and 251. Of 
the two cats that developed swelling in their hindlimb 
without palpable masses, one did not become pregnant 
and the other conceived at day 123. No injection-site reac-
tions were observed in control cats. Tables 2 and 3 detail 
injection-site reactions, pregnancy and fetal numbers.
Discussion
This study evaluated the duration of contraception and 
safety of a single GonaCon injection in adult female cats 
in a simulated free-roaming indoor–outdoor environ-
ment. Conditions were as close to a FRC colony as feasi-
ble while ensuring a closed population, the ability to 
closely and reliably monitor vaccine response and indi-
vidual cat health, and the ability to provide veterinary 
care as needed. Although vaccinated cats demonstrated 
significantly longer time to conception and a reduced 
number of fetuses compared with controls, the study 
found that a single dose of GonaCon provided contracep-
tion lasting for a minimum of 1 year in only 30% (n = 
6/20) of treated cats. In a previous study,1 a GnRH-based 
vaccine (a previous formulation of GonaCon) induced 
fertility control in 100% of treated laboratory cats with a 
duration of contraception that varied from 5 months to 
>5 years, with a median of nearly 40 months.
The poor contraceptive efficacy of this vaccine vs 
prior studies in both female and male cats was not antici-
pated.1,8,9 Three possibilities have been considered.
One possible explanation could be variability in the 
vaccine itself. Although the formulation used in the cur-
rent study was the same as in the GonaCon safety 
Table 2 Time to conception, injection-site reaction incidence and litter size in individual control cats (n = 10) and 
GonaCon-treated cats (n = 20)
Treatment Cat Conception (day) Injection-site reaction Fetuses at spay
Control 1 123 No 8
Control 10 123 No 6
Control 13 123 No 7
Control 20 123 No 6
Control 32 123 No 7
Control 19 132 No 7
Control 7 190 No 4
Control 17 211 No 4
Control 24 219 No 5
Control 23 234 No 2 + 1*
GonaCon 9 123 Yes 4
GonaCon 31 123 Yes 4
GonaCon 28 123 No 1
GonaCon 15 131 Yes 1
GonaCon 8 142 Yes 5
GonaCon 11 142 No 5
GonaCon 37 142 No 2 + 1*
GonaCon 5 145 No 4
GonaCon 14 190 No 6
GonaCon 22 198 No 7
GonaCon 3 226 Yes 3
GonaCon 30 234 No 4
GonaCon 18 251 Yes 4
GonaCon 25 273 No 5
GonaCon 6 NA No NA
GonaCon 12 NA Yes NA
GonaCon 21 NA No NA
GonaCon 27 NA No NA
GonaCon 36 NA Yes NA
GonaCon 38 NA Yes NA
Six cats remained infertile for the duration of the 1 year study
*Resorbed fetus
NA = not applicable
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confirmation study, during which a strong humoral 
immune response was measured in all treated cats,3 the 
two studies used different batches of vaccine. A retro-
spective consideration of standard manufacturing 
 quality-control measures did not offer an explanation for 
differences between the two batches, maintenance of 
appropriate cold-chain handling was well documented 
and the vaccine used in this study did not exceed its 
shelf life. A direct comparative analysis between vac-
cines used in safety confirmation and current studies 
was not performed because both batches had expired at 
the time of inquiry.
A second potential explanation relates to individual 
variability. As with any vaccine, duration of effect is 
expected to vary somewhat among individuals.10 Even 
when breed, age, source and sex were kept consistent 
within previous studies using GnRH-based vaccines,1,8,9 
individual cats responded with a variable GnRH anti-
body production. As increased individual variability 
was an essential part of the current study design, an 
inconsistent response to vaccination within this popula-
tion was plausible.
It is noteworthy that individual variability was also 
observed in the mating responses of control cats in this 
study. Mating and conception was more broadly distrib-
uted in the current study than in the Levy et al study,1 in 
which all of the sham-treated cats (n = 5) became preg-
nant 7–28 days after the introduction of the male. In the 
current study, 6/10 control cats conceived in a similarly 
rapid timeframe, whereas the remaining four control 
cats conceived later, 75–119 days after initiation of the 
breeding trial.
A third potential explanation stems from plausible dif-
ferences between laboratory and free-roaming cat popula-
tions, including environmental conditions. A consideration 
of previous GnRH-based immunocontraceptive studies in 
female white-tailed deer reveals a lesser vaccine efficacy in 
free-roaming populations of wild deer than in penned,11,12 
captive-bred/born populations that received regular vet-
erinary care, housing and a consistent diet.13 However, 
results in deer present a difficult analogy because, while 
history was not known prior to entering the research facil-
ity, cats in this study were normalized to a common plane 
of health, nutrition and environment prior to study initia-
tion, and they received regular veterinary care throughout 
the study. This precludes equating cats in this study with 
the free-roaming wild deer population.
With regard to injection-site reactions, previous stud-
ies of cats treated with GonaCon formulations exhibited 
reactions similar to those seen in this study.1,3 It is possi-
ble that transient reactions in this study went undetected 
after the frequency of palpations changed from weekly 
to monthly. It is also possible that late-onset reactions 
could have developed after cats were removed from the 
study and adopted into homes. These findings are 
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consistent with the aforementioned safety confirmation 
study, in which 4/6 cats developed soft tissue masses at 
the site of injection; three of these developed within a 
month after injection and one developed 8 months post-
injection while in the adoptive home.1,3
Vaccine components that extend duration of response 
are believed to contribute to injection-site reactions.14 
Although the unpredictable timing, type and severity of 
the observed reactions could be perceived as a concern 
for field use of this vaccine, none of the reactions observed 
in the Levy et al laboratory cats,1 the safety confirmation 
study and this field study appeared to cause more than 
transient pain or were considered life threatening.3
The goal of testing a temporary contraceptive in this 
study was to provide a useful tool in the field to manage 
free-roaming cats, as an alternative to surgical steriliza-
tion or as an interim tool prior to the availability of a per-
manent method of non-surgical fertility control. 
Simulation modeling using the GonaCon contraceptive 
results achieved by Levy et al,1 and using a negative long-
term population growth rate as a generic criterion for 
population management success, required treating (or 
retreating) approximately 50% of the fertile cats in the 
population, every 6 months, on a sustained basis. This 
was equivalent to a long-term cumulative infertility rate 
of 75% of cats. Although it was not explicitly modeled, we 
suspect that employing contraception and surgery 
sequentially could be logistically advantageous. More 
specifically, high initial rates of fertility suppression could 
be most quickly achieved by contracepting a large num-
ber of cats, with surgery used over a longer subsequent 
time period to permanently sterilize contracepted cats 
before they revert to fertility.2 Additional research is being 
conducted to better characterize the relationship between 
contraceptive efficacy and population reduction, includ-
ing a comparison of the economic requirements of alter-
native management approaches (J Boone, 2017, personal 
communication). This could provide helpful guidance in 
designing non-permanent contraception for cats.
Conclusions
A 0.5 ml dose of the GonaCon vaccine formulated and 
approved for use in white-tailed deer and wild equid 
species did not provide contraception for a sufficient 
proportion of female cats housed under colony condi-
tions during this year-long study to justify continuation 
of the study or deployment of this immunocontraceptive 
for the control of FRC populations.
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